Navigation Links
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
Date:6/10/2008

ng from blood cancers.

About Provid Pharmaceuticals Inc.

Provid is a drug discovery service company located in North Brunswick, New Jersey, that provides expert medicinal chemistry support to biotech and pharmaceutical industries, and to government labs, research foundations, and academic groups. The company also uniquely offers experimental due diligence (EXPEDD(TM)) to support decisions by academic technology transfer teams, venture investors, pharma and biotech portfolio management groups. The company has a strategic alliance with iNovacia AB in Stockholm that extends drug discovery capabilities via assay development, screening, and biophysical characterization. For more information, see http://www.providpharma.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
6. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
9. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
10. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
11. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on Form 20-F for the fiscal year ended December ... ("SEC"). The annual report on Form 20-F contains information ... in the area of cancer immune checkpoints. This project ... high specificity and binding in targeting certain identified immune ...
(Date:5/4/2015)... May 4, 2015  Traverse Biosciences announced today ... and development agreement (CRADA) with Aratana Therapeutics Inc. ... of TRB-N0224 for the treatment and control of ... cats.  Traverse Biosciences has also granted Aratana an ... and control of periodontal disease in companion animals, ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - Fluorinov ... to announce the appointment of Dr. Roger J ... experience guiding biotech companies in matters including corporate ... leadership team and adds significant regulatory expertise as ... Dr. Garceau brings 30 years of pharmaceutical development ...
(Date:5/4/2015)... 2015 /PRNewswire/ - The Fight Against Cancer Innovation ... announce the formation of Turnstone Biologics Inc. (Turnstone), ... cancer that harness the patient,s own immune system. ... between the Children,s Hospital of Eastern ... the Ontario Institute for Cancer Research (OICR), the ...
Breaking Biology Technology:Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... , VANCOUVER , June 28 /PRNewswire-FirstCall/ - Dragon ... announced that its Special Meeting of Shareholders will be held on ... Time at the Company,s corporate office located at Suite 310, ... 4N9. Only shareholders of record of as of May 28, ...
... 28 Abviva, Inc. (OTC: ABVV), a biomedical company engaged ... Mammastatin, today announced they will be presenting at OneMedForum sponsored by ... 2010. Stifel was recently ranked #1 overall out of 183 qualifying ... on the Street Survey for 2010 . , ...
... ,, CHENNAI, India , June 28, 2010 ... an order worth USD 6 million from the private organizations and,Government ... Kenya , Tanzania and Ethiopia . The company will be ... , , ...
Cached Biology Technology:Dragon Pharma announces date of special meeting 2Abviva to Present at OneMedForum Sponsored by Stifel Nicolaus 2Indian Multinational Company Confirms USD 6 Million Order to Set up Industrial Waste Water Treatment Plants in Africa 2Indian Multinational Company Confirms USD 6 Million Order to Set up Industrial Waste Water Treatment Plants in Africa 3
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... April 11, 2011 (BRONX, NY) Just as inhaling ... it. Two researchers at Albert Einstein College of Medicine ... grant from the National Institutes of Health to clinically develop ... before the cancer becomes malignant and spreads. The grant ...
... SEATTLE, Wash.April 12, 2011The Allen Institute for Brain ... genomically comprehensive human brain map, a previously unthinkable ... than four years of rigorous studies and documentation. ... Allen Human Brain Atlas, an online public resource ...
... material available to identify persons or find next of kin ... the kits usually employed to carry out DNA identifications do ... is not available, and that which is available is highly ... persons from these small fragments of DNA. His thesis, presented ...
Cached Biology News:NIH funds investigation of inhaled lung cancer treatment 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 3Developing a tool for identification -- even using very degraded DNA samples 2Developing a tool for identification -- even using very degraded DNA samples 3
... is designed to knockout or alter genes on ... one week. Red/ET recombination allows the exchange of ... and faithful manner. An FRT-flanked kanamycin resistance marker ... be used to replace a gene on the ...
... a state-of-the-art separation system using the asymmetric ... Eclipse integrates easily with Wyatts multi-angle light ... well as the Optilab DSP. The combined ... distributions of the particles/molecules separated by the ...
... to Rhodopsin Rhodopsin is a glycoprotein ... birds, amphibians, and reptiles. The rhodopsin protein ... the retina. Immunogen: Membrane ... Specificity: This antibody specifically labels the ...
... StabilCoat Immunoassay Stabilizer is an aqueous solution ... other non-toxic chemicals in a PBS buffer ... This product does not contain a ... conformation and activity of dried protein components ...
Biology Products: